A white "Biointelect" logo is displayed against a dark green/black background.
Search
Contact Us
Home › Company › Our People

Our People

With a robust understanding of the life science ecosystem, our Biointelect team possess decades of experience working across a multitude of innovative health projects.

Our Board

Jennifer Herz, Co-founder of Biointelect
Jennifer Herz

Co-founder & Director

Linkedin
Karl Herz, Co-founder of Biointelect
Karl Herz

Co-founder & Director

Linkedin

Our Leadership Team

Leah Goodman, Biointelect's Chief Executive Officer
Leah Goodman

Chief Executive Officer

Linkedin
Brian Gilmartin

Director, Early Stage & Regulatory Affairs

Linkedin
Jacqui Wade

Director, Clinical Affairs & Director Services

Linkedin
Nicola Richards

Director, Commercialisation and Market Access

Linkedin
Katrina Lapham

Director, Policy and Economics

Linkedin

Our Team

Misty Anderson

Business Operations Manager

Linkedin
Sophie Goddard

Manager Consultant 

Linkedin
Dr Jacky Arkell

Senior Consultant – Regulatory Affairs

Linkedin
Dr Quentin Wright

Senior Product Development Consultant

Linkedin
Dr Clare Fedele

Senior Consultant – R&D Strategy and Planning

Linkedin
Tamara Krpan

Senior Project Manager – Clinical Affairs

Linkedin
Dr Alysha Elliott

Project Manager – Clinical Affairs

Linkedin
Swati Nikam Menghani

Senior Clinical Research Associate

Linkedin
Dr Meghna Menon

Associate Project Manager – Clinical 

Linkedin
Karla Montenegro

Clinical Project Manager

Linkedin
Nathan Fox

Health Economics Lead

Nicole Murray

Senior Associate

Linkedin
Vincent Victory

Senior Associate

Linkedin
Athiya Azeem

Associate

Linkedin
Jasmine Perera

Business Insights Associate

Linkedin
Nicki Sidwell

Executive Officer and Marketing Associate

Linkedin
Marcelo Salvatte Pinheiro

Quality Lead

Linkedin
Eva Milbank

Administrative Assistant

Linkedin

Our Biointelect Venturer Team

Danielle Shand

General Manager

Linkedin
Leanne Hobbs

Strategic Advisor

Linkedin
Jeremy Yang

Program Manager (Pre-Award)

Linkedin
Dr Greiciely André

Program Manager (Post-Award)

Linkedin
Dr Meghana Kulkarni

Project Manager

Linkedin
Andrew Bowskill

Partnership and Stakeholder Lead

Linkedin

Careers

Biointelect offer exciting and dynamic opportunities to work with a diverse range of clients on equally diverse challenges in commercialisation of medicines and biotherapeutics, and associated policy issues.

If you are looking to scale your career growth and play an integral role in advancing healthcare for all, why not join one of Australia’s leading biotech consulting firms.

Explore Opportunities
Jennifer Herz, Co-founder of Biointelect

Jennifer Herz

Co-founder & Director

Jennifer Herz, GAICD, co-founded Biointelect and Biocelect to provide end to end strategic commercialisation services to the biopharmaceutical sector. Jennifer has over thirty years commercialisation experience and has held a variety of roles with responsibility for Australia, New Zealand and European markets. She was the first Managing Director of Sanofi Pasteur which was a start-up company and grew significantly to be an established major provider of vaccines in Australia, New Zealand and the Pacific Region. 

 During her time leading Biointelect she has overseen more than 650 projects providing rich and diverse experience in the complexity of life science product development and integrated commercial strategy. This experience includes successful FDA, EMA and TGA approvals and global launches as well as product and company failures, which is where the most learning is gained. 

 Jennifer is a Director of two NASDAQ listed US based biotech company’s Australian subsidiaries and has over twenty years Board experience across publicly listed, private and not-for-profit sectors. Past appointments include membership of NHMRC’s Health Research Impact Committee and the NSW Innovation and Productivity Council Jennifer is also a steering committee member of the Australian AMR Network (AAMRNet) 

 She has previously served on the Board of Medicines Australia as Director and Vice Chair. She was also active in a variety of European and International Industry Association working groups responsible for liaison with health authorities including European Institutions and the WHO. 

Karl Herz, Co-founder of Biointelect

Karl Herz

Co-founder and Director

Karl Herz is one of the co-founders of Biointelect. He has over 25 years of experience in the pharmaceutical industry, holding a Bachelor’s degree in Biomedicine, specialiasing in Biochemistry and Microbiology, and a Post-Graduate Certificate in Marketing from the University of Technology Sydney. His career spans laboratory work and senior management. 

Karl has honed extensive commercial expertise working with numerous multinational pharmaceutical companies, including GSK, Servier and Sanofi. During his career, he gained significant experience collaborating with stakeholders such as hospitals, healthcare specialists, primary care and pharmacy channels within a diverse range of therapeutic areas ranging from over-the-counter, generics, and prescription medicines.  

In his current capacity, Karl serves as a board member of Biointelect and holds the position of Managing Director at Biocelect, a company dedicated to the distribution of pharmaceutical and biotechnology products on behalf of firms seeking to launch their products in the Asia Pacific Region.  

Leah Goodman, Biointelect's Chief Executive Officer

Leah Goodman

Chief Executive Officer

Leah Goodman has over 20 years of Multinational Pharmaceutical leadership experience, including Managing Director ANZ roles with Bristol-Myers Squibb and Merck Healthcare, and more than a decade with Sanofi across commercial Regional responsibilities including Japan, South Korea, Australia/New Zealand as Vice President based in Tokyo, and South East Asian countries as Managing Director based in Malaysia.

 

Through her Industry Association Board leadership across Asia and Australia Leah has played a significant role in market shaping for equitable healthcare access, including as a member of the Board of Medicines Australia from October 2019 to December 2021. Her experience spans innovative biotechnologies across diverse therapeutic areas, as well as across government investment into infrastructure with cell and gene therapy manufacturing in RNA and Viral vectors. Leah has a Bachelor of Science and Masters of Commerce from UNSW, is an AICD Graduate, and has certification in advanced GMP manufacturing.

 

Today, she continues to be active in the Australian LifeScience network, participating as a member of the AusBiotech NSW Leadership Committee, the BioNSW subcommittee on commercialisation, and as a member of the Catalyst Cell and Gene Therapy Policy and Advocacy Working group. She is a member of the Australian Chief Executive Women Network and is an actively passionate advocate for diversity.

Brian Gilmartin

Director, Regulatory Affairs

Brian Gilmartin is a senior leader with more than 20 years of international experience spanning pharmaceutical product development, clinical strategy, operations and commercialisation.

His career began in early-stage drug discovery and bioinformatics within startup environments, followed by work on genome research initiatives, including at the University of Cambridge. He transitioned into the pharmaceutical industry in the mid-2000s, where he established deep expertise in regulatory affairs and technical operations, supporting end-to-end product development across CMC, nonclinical, and clinical domains.

Over the course of his career, Brian has worked across Europe, Asia-Pacific, Japan, US and Australia/New Zealand, providing him with a global perspective on regulatory frameworks and market access pathways. His experience includes leading regulatory strategy for new product registration, lifecycle management, and navigating complex cross-border development programs.

In the past decade, Brian has focused on bridging development and commercialisation by building and supporting pharmaceutical services across the JAPAC region. His work has enabled clinical trial supply, early access programs, unlicensed medicine pathways, and the successful commercialisation of innovative therapies addressing significant unmet medical needs.

Brian has extensive therapeutic expertise across haematology, oncology, cardiovascular disease, and rare diseases. He is particularly experienced in integrating regulatory strategy with clinical development planning and market access considerations to optimise product pathways from early development through to commercial launch.

As Director of Regulatory Affairs at Biointelect, Brian partners with biotechnology and pharmaceutical companies to design and execute global regulatory strategies, support clinical development planning, and enable efficient pathways to market—ensuring alignment between regulatory requirements, evidence generation, and commercial objectives.

Jacqui Wade

Director, Clinical Affairs & Director Services

Jacqui Wade is a senior life sciences leader with more than 30 years of experience across the pharmaceutical, biotechnology and clinical research sectors. Holding a Bachelor of Science with majors in Pharmacology and Physiology, she has built deep expertise spanning clinical development, product commercialisation and strategic program leadership across multiple therapeutic areas, including oncology, neuroscience, HIV, immunology and infectious diseases.

Jacqui’s early clinical career included being part of the establishment of a Phase I clinical trial unit in Adelaide, and leading Phase II–IV development programs at Janssen, along with contributing to global medical affairs initiatives during an international assignment in Canada. She later held commercial leader roles, successfully managing the PBS launches of innovative therapies in prostate cancer and chronic lymphocytic leukaemia and guiding cross‑functional teams through complex, high‑impact product introductions.

Before joining Biointelect, Jacqui served as a Project Director within a CRO, supporting small to medium‑sized biotechs with early‑phase clinical strategy and execution, and held a Director role in a biotechnology company, strengthening her understanding of early‑stage organisational needs.

Since joining Biointelect in 2022, Jacqui has led the growth and delivery of the company’s full‑service CRO capabilities, overseeing early‑phase clinical strategy, study execution and cross‑functional operational leadership. She also oversees Director Services, supporting biotechs entering the Australian market through resident directorship, governance and corporate secretarial support, financial and tax compliance, and access to Australia’s R&D Tax Incentive.

With a career grounded in both scientific and commercial disciplines, Jacqui is recognised for her ability to integrate clinical, regulatory and commercial considerations into clear, actionable development strategies. She partners closely with clients to build capability, reduce risk and accelerate the path from innovation to impact.

Nicola Richards

Director, Commercialisation and Market Access

Nicola has over 30 years’ experience pharmaceutical experience in the full range of commercial roles including sales, marketing and business development. She had been in Executive leadership roles including Market access, Public Affairs, Policy and Commercial operations. She has a Bachelor of Science degree.

Nicola has been heavily involved in health care industry work, including roles an industry representative on the Medicine Australia Strategic Advisory Council, Australian Medicine Working Group (AMWG) sub committee and chair/member of various Medicine Australia working groups relating the Strategic agreements and other relevant industry issues. She is also passionate about contributing to consumer committees for NSW Health including eHealth and SDPR

Nicola joined Biointelect in April 2025.

Katrina Lapham

Director, Policy and Economics

Katrina Lapham has more than 15 years of international experience in the healthcare and biopharmaceutical industries across Australia, the United States, the United Kingdom and emerging markets. She holds a Master of Science from the London School of Economics, Policy and Management and a Bachelor’s in Economics (Honours) from the University of Western Australia. Her professional portfolio encompasses policy design and evaluation, funding model analysis, and program evaluation. 

Early in her career, Katrina began as a health policy analyst within the Australia Government Treasury and then joined Deloitte as an Associate Director of Health Economics and Social Policy. Later, she relocated to London, where she led market access strategy, policy and real-world evidence-generation projects. She has had broad exposure across the healthcare sector, collaborating with government bodies, industry , patient advocacy groups and other non-profit organisations. In recent years, she directed two multi-country real-world evidence studies focusing on neurodegenerative diseases.  

Katrina joined Biointelect in 2020 as the Director of Strategic Market Access and Policy, leading numerous projects with biopharmaceutical companies, government agencies and patient organisations. Her expertise contributes to the development of actionable strategies and support in areas such as reimbursement submissions, policy white papers, stakeholder engagement, internal workshops and reports.  

Misty Anderson

Business Operations Manager

Misty brings over 12 years of experience across business operations, transformation, and MarTech, working with both large enterprises and SMEs. She holds a Master of Business Administration from Macquarie University and is a certified PRINCE2 Project Management Practitioner.

Throughout her career, Misty has led complex, high‑value initiatives that deliver meaningful commercial and operational outcomes. In 2025, she managed a $1.6M portfolio of digital transformation programs, leading cross‑functional teams across multiple regions and helping organisations build internal delivery capability for first‑time platform implementations. She works closely with executive stakeholders to shape roadmaps, manage risk, and turn strategic priorities into clear, actionable programs of work.

Misty joined Biointelect in April 2026 and is focused on strengthening, managing, and continuously improving the company’s internal business operations to support sustainable growth.

Sophie Goddard

Manager Consultant

Sophie holds a Bachelor of Commerce with majors in Marketing and International Business and a Bachelor of Advanced Studies in Business from the University of Sydney. 

Prior to joining Biointelect, Sophie began her career in KPMG’s Management Consulting division in the Policy, Economics, and Public Impact team. In this role, she supported a diverse range of clients within the Health and Aged Care sector. Sophie gained valuable experience during her studies by working with Accenture in the United Kingdom as an external student consultant. Here, she collaborated with an interdisciplinary team to design digital solutions for the UK National Health Service, addressing key health challenges faced by elderly populations. 

Sophie joined Biointelect in 2022 in the Strategic Market Access and Policy team. In her role at Biointelect, Sophie supports clients in navigating policy, developing strategies, and driving implementation. Her experience with Biointelect has further enriched her understanding of the healthcare and biopharmaceutical sector, including its operational environment, workflow, and strategic priorities. Sophie has contributed to the development of business cases, conducted commercial assessments, crafted strategic plans, designed operational models, evaluated programs, engaged stakeholders, and managed projects. Her work has spanned various therapeutic areas, including genomics and regenerative medicine. 

Jacky Arkell

Senior Consultant – Regulatory Affairs

Dr Jacky Arkell brings over 20 years of Regulatory experience within the pharmaceutical and medical technology industry. She holds a PhD from the University of Sydney, starting her career in medical research, in the areas of endothelial cell and angiogenesis research, rheumatoid arthritis and in-vitro reproduction at Royal North Shore Hospital, Sydney.

Over 10 years at Alexion Pharmaceuticals, a rare disease company acquired by AstraZeneca in 2021, Jacky successfully registered and launched multiple orphan drugs in Australia and Asia, and held various leadership positions across global, Australia and Asia Pacific teams. Therapeutic areas included rare haematological disorders and genetic metabolic disease and regulatory support included implementing patient registries and utilising accelerated pathways.

Jacky spent another decade at Roche Pharmaceuticals where she utilised her diagnostic registration experience to support various personalised medicine and pan-tumour therapies. She managed the HER2 medicine portfolio, registering the first antibody drug conjugate in Australia for HER2 breast cancer.  Earlier in her career, Jacky worked at Alcon Laboratories, maintaining OTC and prescription eye drops registrations and supporting the ophthalmology surgical business.

She brings cross functional expertise across Pharmacovigilance, Medical Compliance and Quality Assurance/Supply Chain and deep system experience including information management systems, regulatory data analytics and quality management systems.

Jacky joined Biointelect in December 2024.

Quentin Wright

Senior Product Development Consultant

Dr Quentin Wright is an experienced life sciences operator with 17+ years in the United States preclinical pharmaceutical R&D space complemented with recent employment in academia and government. He holds a PhD in immunology from the University of Queensland and a master’s degree in immunology from Harvard University.  His expertise spans immunology, infectious diseases, virology, oncology, microbiology, metabolism, translational research, drug development and regulatory affairs.

He brings experience in global pharmaceutical organizations such as Pfizer, GSK and Moderna, in addition to venture backed startups such as Verastem and Immunext, supporting activities such as proof of concept/mechanism, in vivo/in vitro studies, lead candidate selection and tox studies.

His efforts have supported the FDA approval of one oncology asset, and the out-licensing of assets to 2 multinational pharmaceutical organisations.

Quentin relocated to Australia in 2018. During his time at UQ, he developed novel immunomodulatory antibody therapy delivery strategies to cutaneous cancer models, solving systemic toxicity issues normally observed with 2+ antibodies applied in these settings.

Recently, he transitioned to CSIRO’s Australian Centre for Disease Preparedness, where he deployed and scaled multiomics capabilities supporting vaccine development studies. This work later enabled the organisation to win competitive contracts, supporting research aimed at boosting sovereign food security and productivity in APAC countries.

Quentin leverages a unique cross-domain background, broad therapeutic modality experience and first-hand experience of emergent and contemporary research platforms supporting early discovery and translational research activities.

Quentin joined Biointelect in 2026.

Dr Clare Fedele

Senior Consultant R&D Strategy and Planning

Dr Clare Fedele brings over 20 years of experience in the life sciences sector, spanning academic research, science/health communication, research project management and biopharmaceutical R&D.

She holds a PhD in Biochemistry and Molecular Biology from Monash University, specialising in oncology. Clare held the position of Senior Research Scientist in Translational Research at CSL, supporting progression of assets through the R&D pipeline. While at CSL Clare specialised in the cardiovascular and renal therapeutic area, helping to grow CSL’s Research portfolio. Prior to this she held senior research roles at The University of Melbourne Centre for Cancer Research and Peter MacCallum Cancer Centre. Clare has co-authored more than 25 peer-reviewed scientific publications and contributed to multiple successful competitive grants.

She has been the recipient of multiple awards, including postdoctoral fellowships from NHMRC and Victorian Cancer Agency, and was a Science and Technology Australia Superstar of STEM. Clare joined Biointelect in 2025 as part of the R&D Strategy and Planning team. Clare applies her extensive experience in life sciences research to provide strategic support to clients to drive progression of research into commercial success.

Clare joined Biointelect in April 2025.

Tamara Krpan

Senior Project Manager – Clinical

Tamara Krpan brings over 20 years of combined Project Management & Clinical Operations experience in both Pharmaceutical and Clinical Research Organisation Industry.

She holds Bachelor of Science (Nursing). Most recently working in a global project lead role, leading key stakeholders within the global team to ensure project delivery to quality, time and budget. Historically Tamara managed regional & global phase 1-4 studies, including feasibility, start up processes, site and project management, especially excelling in building strong interpersonal relationships with both internal and external teams.

Tamara Krpan joined Biointelect in 2026, as Senior Project Manager, contributing a wealth of experience in Oncology to support building our Clinical Trials presence locally and globally.

Dr Alysha Elliott

Project Manager – Clinical Affairs

Dr. Alysha Elliott has over 15 years of experience in the Life Sciences industry. She holds a Ph.D. in Molecular Bioscience from the University of Queensland, focusing on drug discovery. Her expertise spans molecular biology, microbiology, biochemistry and antimicrobial drug development.  

Throughout her career, Alysha managed preclinical evaluations of novel antimicrobials, led a crowd-sourcing screening program with over 330 participant groups, and conducted contract research for Biotech companies. She received the prestigious Endeavour Executive Fellowship in 2018, gaining commercialisation experience at Cambridge Enterprise (UK) and the biotech start-up Inflazome Pty Ltd, later acquired by Roche in 2020. Alysha’s work has resulted in over 70 peer-reviewed research articles and numerous awards, including the Antibiotic Guardian award for Research UK, finalist recognition in The Australian Innovation Challenge, Australian Museum Eureka Prizes, and the AusBiotech-GlaxoSmithKline Student Excellence Award in Translational Research. Her interdisciplinary infectious disease research attracted funding from globally recognized bodies such as the Wellcome Trust (UK), the National Institutes of Health (NIH, USA), and CARB-X (Combating Antimicrobial Resistant Bacteria Biopharmaceutical Accelerator), supported by BARDA, GAMRIF, Wellcome, the Bill and Melinda Gates Foundation, among others. 

Alysha joined Biointelect in 2023 as a Project Manager, providing expertise in infectious diseases and facilitating the development of innovative therapies and diagnostics. 

Swati Nikam Menghani

Senior Clinical Research Associate

Swati Nikam Menghani brings over 12 years of experience in the healthcare sector, including clinical support and consulting, clinical research, clinical trials site management and monitoring for complex trials. She holds a Master of Biotechnology (Medicine), while continuing her studies in Integrative Health. Prior to joining Biointelect, Swati led monitoring activities for complex First-in-Human trials in Oncology, Gene Therapy and Paediatric Rare Diseases, delivering critical study milestones for sponsors and CROs alike.

She has successfully managed multi-site multi-phase clinical trials across diverse therapeutic areas including Maternal Health, Immunotherapy, and Chronic and Infectious Diseases, earning recognition for high-quality monitoring while also working independently in a clinical consulting capacity.

Swati joined Biointelect in 2026 as a Senior Clinical Research Associate to support clinical trial delivery across the growing portfolio of Biointelect’s clinical operations.

Dr Meghna Menon

Associate Project Manager, Clinical Affairs and Director Services

Dr Meghna Menon brings over three years of experience in clinical research, with expertise in clinical trial operations, clinical project oversight, study start-up, site management, eTMF management and stakeholder engagement. She holds a Master of Public Health from the University of Melbourne and a Bachelor of Dental Surgery.

 

Prior to joining Biointelect, Meghna worked at GenesisCare CRO, where she supported the project management team with site start-up and overall study management activities, while maintaining inspection-ready eTMF systems across Phase I and II oncology and radiopharmaceutical studies, including theranostics. She has also previously worked at Avance Clinical, supporting the clinical operations team with day-to-day deliverables and coordinating stakeholders across multiple studies. Her experience spans a range of therapeutic areas, including oncology, immunology, cardiology, neurology and radiopharmaceuticals. Meghna began her career as a dentist, which gives her a strong clinical foundation.

 

Meghna joined Biointelect in September 2026 as an Associate Project Manager, supporting the delivery of Clinical Affairs and Director Services projects, with a focus on trial operations, documentation and project coordination for early-stage biotech and MedTech clients

Karla Montenegro

Clinical Project Manager

Karla Montenegro brings more than 15 years of experience in clinical research, with expertise spanning Phase I, II, III and IV clinical trials across a broad range of therapeutic areas including oncology, cardiometabolic diseases, infectious diseases, immune-mediated inflammatory diseases and gastroenterology. She has a particularly strong background in early-phase clinical research and healthy volunteer studies. Karla holds a Masters in International Health from Heidelberg University and a Bachelor in Pharmaceutical Chemistry from Universidad San Carlos de Guatemala. She is fluent in both English and Spanish.

Most recently, Karla has been working as a freelance Clinical Lead CRA and Project Manager, leading clinical trial delivery and coordinating multidisciplinary teams across clinical operations, data management, biostatistics, and regulatory affairs. Prior to this, she spent more than seven years with Fortrea (formerly Labcorp/Covance), progressing from CRA II through to Project Manager within Global Project Delivery. In these roles, she was responsible for end-to-end project delivery, client relationship management, risk management, quality oversight, and cross-functional team leadership.

Joined Biointelect in 2026, contributing play a key role in supporting the successful delivery of clinical trials across our expanding portfolio and strengthening our project management capabilities.

Nathan Fox

Health Economics Lead

Nathan Fox has almost ten years of experience consulting in pharmaceuticals, medical services, and devices across Australia, New Zealand, APAC, and Europe. He holds a Master of Economics and Public Health and a Bachelor of Economics & Commerce. His expertise spans health technology assessment, reimbursement systems and processes, policy, and economics. 

Throughout his career, he has successfully developed submissions for global pharmaceutical companies to the Pharmaceutical Benefits Advisory Committee (PBAC), the Pharmaceutical Benefits Schedule (PBS) in Australia and New Zealand’s Pharmaceutical Management Agency (PHARMAC), gaining expertise in product positioning and economic and financial modelling. Nathan also worked at PHARMAC reviewing the therapeutic positioning and health economic and financial implications of potential funding options for medicines, vaccines, and rare diseases.  During this time, Nathan has contributed to more than 50 HTA evaluations across a diverse range of therapeutic and disease areas.

Nathan joined Biointelect in 2021 as a Consultant in the Strategic Market Access & Policy team. His contributions have included advising vaccine and rare disease companies on funding submissions and negotiations, authoring published position papers for Medicines Australia, and academic articles for the industry. Additionally, Nathan has delivered a commercialisation valuation cost-benefit analysis submission to the state government and guided early-stage product developers and clinical trial industry operators on product value propositions and economic impact assessments for technology precincts.

Nicole Murray

Senior Associate

Nicole brings over 4 years of Market Access, HEOR and Business Excellence. She holds a Masters degree in Health Economics and a Bachelor Honours degree in Human Nutrition.

Prior to joining Biointelect, Nicole worked at Novartis Australia, where she drove business excellence and execution. In this role, she supported an Australia‑wide project focused on maximising therapeutic assets through the use of artificial intelligence. Nicole previously served as a Market Access Manager in rare diseases at Sanofi Aventis, where she successfully led the economic analysis and reimbursement submission for the LSDP.

Nicole’s pharmaceutical career began in a global role with Novartis Ireland as a HEOR Graduate, where she later progressed to an Analyst position, supporting multiple therapeutic areas across product launches and early access programmes.

Nicole joined Biointelect in 2026 as a Senior Associate in Commercialisation and is currently supporting commerclisation, market access and policy projects across biopharmaceutical companies, government agencies, and patient organisations.

Vincent Victory

Senior Associate

Vincent holds a Master of Biotechnology and a Bachelor of Biomedicine with a major in Pathology from the University of Melbourne.

With over 3 years of consulting experience in the life sciences industry, Vincent specialises in commercialisation, market access, and stakeholder analysis for pharmaceutical and MedTech clients. In his previous role at Commercial Eyes, Vincent led a range of successful projects spanning major Australian reimbursement submissions (PBAC, MSAC, and the Prescribed List), pricing strategy and negotiation, competitive intelligence, financial modelling, and go-to-market plans for both early and late-stage clients. Vincent has delivered projects across a diverse range of therapeutic areas and multiple geographies, including Australia, New Zealand, Singapore, and Japan.

 

Vincent joined Biointelect in February 2026 in the Market Access, Policy and Commercialisation team. In his role, he supports clients in navigating complex treatment and payer landscapes and in developing robust commercialisation strategies. He has a particular interest in both traditional and emerging reimbursement pathways, helping clients identify innovative routes to market. He is particularly passionate about bridging scientific innovation with sustainable patient access.

 

Athiya Azeem

Associate

Athiya brings experience across scientific research, product development, and early‑stage commercialisation. She holds a PhD from the University of Sydney, specializing in the fluid mechanics of dry powder inhalers for improved pulmonary drug delivery.

Her recent work includes leading the commercialisation efforts for a university spin‑out, where she secured pre‑seed funding, established partnerships for product trials, and engaged potential licensees and collaborators.

Athiya joined Biointelect in 2026 as an Associate contributing to strategic analysis and commercial support across Biointelect’s portfolio of health and biotech projects.   

Jasmine Perera

Business Insights Associate

Jasmine brings over two years of experience in the life sciences industry, with expertise in market research, stakeholder engagement, and market access. She holds a Master of Biotechnology from the University of Melbourne and a Bachelor of Science, majoring in developmental biology.

In her previous role at Commercial Eyes, Jasmine has led both qualitative and quantitative research, competitor landscape assessments, and go-to-market strategies for both global and early-stage clients across the pharmaceutical and medical device sectors. She also contributed to regulatory and reimbursement submissions to the TGA and PBAC.

Jasmine joined Biointelect in July 2025, where she contributes to strategic business growth by identifying and engaging with potential leads and opportunities. She supports cross-functional teams in connecting with prospective clients and strengthening commercial strategies through targeted, data-informed insights.

Nicki Sidwell

Executive Officer and Marketing Associate

Nicki Sidwell holds a Certificate 4 in Business through Macquarie Business College and completed a Scrum Master training in Agile Project Management through Epic Consulting Services. 

Previously, Nicki worked at Novartis Oncology for 18 years. During her time there, Nicki provided marketing and sales support across the key marketed Oncology brands. Event management of Novartis Sales Conferences and Scientific Meetings. Her recent position was the Customer Operation Manager for the logistical management of Novartis’ CAR-T therapy in Australia.  

Nicki joined Biointelect in 2023 as a Project Officer, supporting the consulting teams and their clients to achieve the best results for them.

She transitioned into the role of Marketing Associate in April 2024, where she plays a key role in driving marketing initiatives, crafting compelling campaigns, and enhancing brand visibility. Her focus is on optimizing digital marketing efforts, and engaging target audiences to elevate the company’s presence in the marketplace. 

She moved into the role of Executive Officer in December 2024, where she plays a pivotal role in supporting the leadership team, coordinating events, and overseeing office management to ensure seamless operations.

Marcelo Salvatte Pinheiro

Quality Lead

Marcelo holds a B.Sc in Biomedical Sciences from the Federal University of Mato Grosso, Brazil, where he contributed to the Laboratory of System Physiology and Reproductive Toxicology. He also completed an internship at the Molecular Genetics Laboratory at the University of Nebraska Omaha, USA.

Throughout his career, Marcelo has managed complex projects across diverse therapeutic areas in the clinical trials industry, from first-in-human to post-marketing trials. In his recent role as a Clinical Quality and Training Associate, he optimized processes and lead teams through successful audits.

Marcelo joined Biointelect in 2024, bringing his passion and expertise in quality and compliance. He focuses on quality management systems (QMS) and collaborates with various functional areas to deliver high-quality results in a dynamic environment

Eva Milbank

Administrative Assistant

Eva Milbank brings over 20 years of experience in office management and workplace operations, with expertise in daily office management, team support, facilities and front of house and executive support.  She holds a Bachelor of Commerce from the University of Tasmania.

Most recently, Eva was Team Assistant in at WPP, supporting a team of internal and contracted staff. Before that, she was Office Manager at EssenceMediacom, running a 260-person office, and at Resolution Capital. Earlier in her career she held operations and administration roles at Dynata, Lightspeed Research, Global Market Insite and Johnsons Corporate.

Eva joined Biointelect in 2026, contributing as Administrative Assistant, supporting the Biointelect and Biointelect Venture teams with admin duties and keeping the office and day-to-day operations running smoothly for the team.

 

Danielle Shand

General Manager, Biointelect Venturer

Danielle Shand has over 20 years’ experience in the pharmaceutical and medtech sectors, including seven years leading national programs and initiatives that connect industry, research, and Australia’s broader innovation ecosystem.

Prior to joining Biointelect, Danielle held senior leadership roles at MTPConnect, where she led and managed teams to deliver more than $43 million in Medical Research Future Fund (MRFF) investment through the Biomedical Translation Bridge (BTB) and Clinical Translation and Commercialisation (CTCM) Medtech Accelerator programs. She oversaw the strategic planning, governance, and operations of these national initiatives, supporting 33 funded projects, advancing 65 Australian medtech and pharmaceutical technologies, and generating significant follow-on investment across the MTP sector.

Danielle brings expertise in program delivery, governance, grants management, strategic planning, and financial oversight, with 13 years’ earlier experience at Pfizer.

Danielle joined Biointelect in 2026 and is based in Sydney, where she serves as General Manager of Biointelect Venturer. In this role, she leads the strategic design and delivery of the federally funded incubator, supporting emerging companies and academic innovators to advance vaccine and related technologies toward investment and commercial readiness.

Leanne Hobbs

Strategic Advisor

With 30 years of experience in the biotech, vaccine, and pharmaceutical industries across both local and international landscapes, Leanne is a highly respected leader in product development and commercialisation strategy. Formerly CEO Sementis Ltd (Australia) and as Global Senior Executive at GSK Vaccines (Belgium), Leanne has led diverse teams in developing and commercialising vaccines and medical technologies across a wide range of disease areas, geographies, and investment levels. She also contributes her expertise as a Board Commercialisation Committee Member at WEHI (Walter and Eliza Hall Institute of Medical Research), AusBiotech (SA Committee) and Health Security Systems Divisional Advisory Panel. She is mentor to several biotechnology start-ups, helping guide strategic decisions to support translation of cutting-edge research into impactful medical solutions.

With an extensive Australian and global network, Leanne connects biotech companies with the right expertise at the right time. She has been deeply engaged in the start-up ecosystem locally and internationally as a pitch judge, mentor, and expert advisor, with broad experience in incubator and mentoring programs and a deep understanding of what makes successful products, teams and companies. Passionate about fostering innovation and economic growth, she is committed to making a meaningful impact by helping bring life-changing technologies to the people who need them most.

She holds a Bachelor of Science (Hons) from the University of Adelaide, post-graduate qualifications in Pharmaco-economics (Monash University) and Start-up Board Directorship (École Polytechnique Fédérale de Lausanne) and is a Graduate of the Australian Institute of Company Directors (GAICD).

Leanne Hobbs is Strategic Advisor to Biointelect Venturer, following her foundational leadership as the program’s inaugural General Manager. She continues to guide strategic direction, ecosystem engagement, and partnership development for the incubator.

Jeremy Yang

Program Manager (Pre-Award)

Jeremy Yang brings over six years of experience supporting the commercialisation of innovative healthcare solutions across consulting and innovation ecosystems. He holds a Bachelor of Science (Honours) and a Master of Biotechnology from the University of Melbourne.

Prior to Biointelect, Jeremy supported the commercialisation of health and medical technology innovations at Swinburne University of Technology, with a focus on venture creation, securing investment and facilitating impactful partnerships. Before this, he spent five years at Commercial Eyes where he worked across healthcare commercialisation, market assessment, regulatory strategy and market access projects supporting innovative health technologies.  

Jeremy joined Biointelect Venturer in 2026 as a Program Manager (Pre-Award) and is based in Melbourne. He plays a key role in delivering the pre-award program lifecycle, including identifying high-potential opportunities, application and assessment processes, due diligence activities, stakeholder coordination, and supporting the assessment of promising vaccine and infectious disease prevention technologies for incubation support.

Dr Greiciely André

Program Manager (Post-Award)

Dr. Greiciely André brings over 10 years of experience in translational research, vaccine development, and project delivery across academic and industry settings. She holds a PhD in Molecular and Cellular Biology focused on vaccine development and has led early phase vaccine programs from discovery through to human clinical trials. She has managed cross functional teams and development contracts valued at more than USD $20 million, including major awards funded by the US National Institutes of Health (NIH).

A key achievement in her career includes contributing to the development and Emergency Use Authorization of the SpikoGen® COVID 19 vaccine, the first recombinant protein vaccine to reach this milestone, and its AI designed adjuvant, an early example of an AI guided component incorporated into a licensed human vaccine. Her expertise also spans preclinical research, GMP manufacturing, clinical trials, and regulatory compliance, enabling her to bridge scientific innovation with operational and commercial execution.

Dr. Greiciely joined Biointelect Venturer in 2026, where she supports emerging companies and academic innovators in progressing infectious disease technologies toward investment and commercial readiness. As Program Manager (Post-Award), she leverages her technical and operational expertise to guide SMEs through translation pathways, contributing to the Biointelect Venturer incubator’s mission of accelerating breakthrough vaccine and related technologies.

Meghana Kulkarni

Project Manager

Dr Meghana Kulkarni brings over five years of experience in the global health and life sciences sector. She holds a Master of Biomedical and Health Sciences from Monash University and a Bachelor of Dentistry.

Prior to joining Biointelect, Meghana worked at the WHO Collaborating Centre for Antimicrobial Resistance at the Doherty Institute, where she managed an internationally funded fellowship program across the Asia-Pacific, focused on strengthening research and surveillance capacity across five countries. She also served as Project Manager at MTPConnect’s Australian Antimicrobial Resistance Network (AAMRNet), supporting national stakeholder engagement and cross-sector collaboration.

Meghana joined Biointelect Venturer in April 2026 as a Project Manager and is based in Melbourne. She supports the delivery of the MRFF-funded incubator, contributing to program execution, stakeholder engagement, and communications that enable SMEs to develop and commercialise innovative health technologies.

Andrew Bowskill

Partnership and Stakeholder Lead

Andrew Bowskill brings around 30 years’ experience in the healthcare and pharmaceutical industry as a clinician pharmacist, and more recently in stakeholder engagement, strategic policy and advocacy, government relations, communications, corporate partnerships and business development.

Previously, Andrew was Director of Stakeholder Engagement for Queensland at AUScelerate – formerly MTPConnect, facilitating collaboration at the academic research and industry interface. He also led the Australian Antimicrobial Resistance Network (AAMRNet), a public-private, multi-stakeholder expert group promoting Australia’s role in the global fight against antimicrobial resistance (AMR).

Andrew has also had roles at Medicines Australia, the peak body for the innovative pharmaceutical manufacturers in Australia, where he was Manager of Industry and Regulatory Policy, and the Australian College of Nursing.

Andrew joins Biointelect as Partnership and Stakeholder Lead for Biointelect Venturer, Australia’s national incubator for infectious disease innovation. Here he works with Australian SMEs developing infectious disease innovations to accelerate their path from discovery to impact.

Andrew also sits on the World Health Organization Civil Society Task Force on AMR steering committee.

With a Bachelor of Pharmacy from the University of Otago and extensive experience as a pharmacist in both community and hospital settings in Australia and New Zealand, Andrew is a passionate advocate for equitable access to medicines for all patients.

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.